These findings establish that targeted activation of the AMPK/SIRT1/PGC‐1α pathway represents a novel multidimensional therapeutic paradigm for PD, simultaneously addressing protein homeostasis maintenance, oxidative stress mitigation, and mitochondrial functional recovery. This evidence concerns the gene PRKAA1 and Parkinson disease.